Changes in body weight by baseline characteristics of patients
ONCOLOGY
The changes in body weight from baseline to week 12 are compared between anamorelin and placebo in each subgroup in Figure Subgroup analysis of changes in BW at 12 weeks according to sex, age, Alb, albumin; BMI, BW loss within 6 months, ECOG PS, and concomitant anticancer therapy. BMI, body mass index; BW, body weight; CI, confidence interval; CRP, C‐reactive protein; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR‐TKI, epidermal growth factor receptor tyrosine kinase inhibitor; LS, least‐squares; OR, odds ratio.